Market Outlook:
The Global Leukocyte Reduction Filter Market was estimated at USD 291.9 Million in 2022 and is anticipated to reach USD 451.4 Million by 2031, expanding at a CAGR of 5.1 % during the forecast period.
Leukoreduction is the removal of leukocytes from blood components. Each leuko-reduced product has residual leukocyte counts of less than 5×106 cells per unit. Leukoreduction is performed using Leukocyte Reduction Filters (LRFs) that trap leukocytes, while allowing the desired blood product to pass through.
Leukoreduction reduce adverse transfusion reactions such as febrile non-hemolytic transfusion reactions (FNHTR), alloimmunization against human leukocyte antigens (HLA) and human platelet antigens (HPA), which cause refractoriness to platelet transfusion, and transmission of infectious diseases. Additionally, leukoreduction prevent the release of leukocyte metabolites, such as cytokines and histamine. These metabolites contribute to adverse reactions and increase the percentage of hemolysis in red blood cell (RBC) products.
Impact of COVID-19:
The research report finds that the outbreak of COVID-19 pandemic had a negative impact on the market. Social distancing measures caused a decrease in blood donations, which in turn reduced the demand for leukocyte reduction filter. The pandemic's initial focus on managing COVID-19 cases diverted resources from elective surgeries, which are major users of reduction filters. This led to a temporary decline in demand for leukocyte reduction filter.
The impact of COVID-19 on the leukocyte reduction filter market was initially negative, leading to short-term disruptions and decline in demand. However, the long-term outlook appears positive, due to rising blood safety awareness, potential new applications like plasmapheresis, and the growing adoption of e-commerce in the healthcare industry.
Artificial Intelligence (AI) Impact on the Leukocyte Reduction Filter Market:
Artificial Intelligence (AI) has a positive impact on the leukocyte reduction filter market. The emergence of artificial intelligence is expected to provide substantial growth to the market. AI has the potential to revolutionize the leukocyte reduction filter market by enhancing filter design, simplifying the production process, customizing transfusions, and optimizing blood bank management software.
Artificial intelligence (AI)-driven modeling and simulation enhance LRF designs, resulting in filters with improved capacity, efficiency, and selectivity for eliminating leukocytes and minimizing red blood cell loss.
Machine learning algorithms analyze vast amounts of data on blood components and filter performance to identify patterns and predict effective filter design for different blood types and therapeutic needs.
Personalized LRF selection for every patient is guided by AI-based analysis of patient data, which helps predict unique responses to transfusions and maximizes transfusion efficacy while avoiding adverse reactions.
Market Dynamics
Market Driver- Rising Prevalence of Leukemia
Leukemia is type of blood cancer that begins in the bone marrow in which abnormal blood cells, called blasts, are produced replacing healthy ones. It is life-threatening, if left untreated. The incidence of leukemia varies between pathological types and population. Acute myeloid leukemia (AML) is the most common type in adults accounting for 1.3% of new cancer cases in the USA. Acute lymphocytic leukemia (ALL) is more frequent in children with incidence peaks between 2 and 5 years of age.
-
In 2018, a total of 437.0 thousand new cases were reported and 309.0 thousand cancer deaths were caused due to leukemia worldwide.
-
According to the American Cancer Society, in 2020 about 1.32 million individuals were diagnosed worldwide with leukemia and lymphoma.
-
According to Leukemia & Lymphoma society, an estimated 1,629,474 people in the US are living with or in remission from leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPNs).
As a result, high prevalence rate of chronic diseases has increased the demand for blood and blood supplies, which in turn, is projected to increase the demand for leukocyte reduction filter during the forecast period.
Market Driver- Rising Number of Blood Donations
The need for blood and blood products is increasing every year in many countries. The risk of transmission of serious infections, including HIV and hepatitis, through unsafe blood and blood shortages brought global attention to the importance of blood safety and availability.
-
According to World Health Organizations, around 79 countries collect more than 90% of blood supply from voluntary unpaid blood donors. However, 54 countries collect more than 50% of blood supply from family/replacement or paid donors. Based on samples from 1,000 people, the blood donation rate is 31.5 in high-income countries, 15.9 in upper middle-income countries, 6.8 in lower middle-income countries, and 5.0 donations in low-income countries.
-
In 2022, the percentage of blood donations from voluntary unpaid donors has increased and 73 countries in the world.
Hence, increase in blood donations is expected to increase the demand for leukocyte reduction filters during the forecast period.
Market Restraint- Increasing Demand for Apheresis Technique for Blood Transfusion
Apheresis technology is used to enable operators to collect specific blood components. Apheresis collects specific blood components, offering a number of advantages compared to the entire blood collected manually. The apheresis method has proved to be a beneficial alternative to the LRF, thus restraining the growth of the market.
-
According to America’s Blood Centers, an estimated 10,879,000 total whole blood and apheresis red blood cell (RBC) were collected in 2019. Of all US blood donors, 51 percent are male and 49 percent are female.
Market Opportunity- Rising Investments in Life Science
The life science industry has seen the venture investment boost throughout without any interruptions. Heavy investment funds in 2018 and 2019 were dedicated to life science firms, which resulted in high funding for healthcare. A majority of industries have been hampered due to the pandemic; however, the life science industry has remained an active industry for private and initial public investments.
The maximum level of investment in private life science firms was conducted between January and August 2020. New life sciences and digital care opportunities range from telehealth, remote patient care, digital therapies, to new algorithms for improved patient awareness, diseases, the follow-up to treatment, and dissemination of real-time information in therapy areas.
Scope of the Report
The report on the global leukocyte reduction filter market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Leukocyte Reduction Filter Market– Global Industry Analysis, Size, Share, Growth, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016 and 2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
By Type (Whole Blood Filtration, Red Blood Cell Filtration, Platelet Filtration, and Plasma Filtration), By Filter Type (Membrane, Antibacterial, Antiviral, and Pocket), By Usage (Single-Use and Reusable), and By End-use Verticals (Hospitals, Blood Banks, Laboratory, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered
|
Fresenius Kabi AG (Fresenius SE & Co. KGaA); Haemonetics Corporation; Macopharma; TERUMO BCT, INC. (Terumo Corporation); Nanjing Shuangwei Biotechnology Co., Ltd.; Bıçakcılar; SB-KAWASUMI LABORATORIES, INC.; PuriBlood Medical; Nanjing Sunway Biomedical Technology Co., Ltd.; Guangzhou Daji Medical Science and Technology Co., Ltd.; Shandong Zhongbaokang Medical Implements Co., Ltd.; Mitra Industries (P) Ltd.
|
Segmental Outlook
On the basis of type, the global leukocyte reduction filter market is segmented into whole blood filtration, red blood cell filtration, platelet filtration, and plasma filtration. The whole blood filtration segment is projected to expand at a rapid pace during the forecast period as it helps in treating wider range of conditions. Whole blood filtration removes harmful substances or pathogens from whole blood, making it usable for a broader range of therapeutic applications such as sepsis, and autoimmune diseases.
Increasing demand for blood and plasma from the geriatric population globally is projected to fuel the market growth. Rising blood and plasma donations worldwide and favorable blood-screening government regulations are estimated to drive the market.
The platelet filtration segment is expected to grow at a rapid pace during the forecast period due to Increased demand for platelet-rich plasma (PRP) therapy.
Based on filter type, the global leukocyte reduction filter market is segregated into membrane, antibacterial, antiviral, & pocket. The antibacterial segment is expected to hold a significant share of the market during the forecast period as it helps purify blood products and reduce the risk of transfusion-related complications and infections. The filter incorporates antibacterial agents to further enhance the prevention of microbial contamination. It ensures safety and efficacy of blood components during the transfusion.
On the Basis usage, the global leukocyte reduction filter market is bifurcated into single-use & reusable. The single-use segment is expected to hold a significant share of the market during the forecast period as it maintains optimal filtration efficiency. It helps reduce the potential contamination and infection.
Single-use leukocyte reduction filter is a valuable tool for improving the safety and efficacy of blood transfusions. They are widely used in hospitals and blood banks around the world and are an essential part of modern blood banking practices.
In terms of end-use verticals, the global leukocyte reduction filter market is segregated into hospitals, blood banks, laboratory, & others. The Laboratory segment is projected to expand at a significant pace, as large number of disease screening prior to transfusion therapy are majorly performed in the laboratories. The demand for blood transfusion diagnostic such as blood component separators, apheresis, and other consumables is high in diagnostic laboratories.
Regional Outlook
On the basis of regions, the global leukocyte reduction filter market is segmented into North America, Europe, APAC, Latin America, and the Middle East and Africa.
North America is estimated to maintain its dominance in the market during the forecast period, due to increasing demand for leukocyte reduction filter from hospitals.
The market in Asia Pacific is expected to grow at a rapid pace during the forecast period. The growth is anticipated due to rising leukocyte reduction filter production in countries such as China and India.
The market in Europe is projected to expand at a substantial CAGR. Improved healthcare infrastructure, rising disposable incomes, and an increasing focus on blood product safety are key factors contributing to the growth of the market.
Latin America and the Middle East & Africa (MEA) are anticipated to hold a considerable share of the global Leukocyte Reduction Filter market. Government initiatives promoting blood safety and transfusion practices boost the market.
Key Benefits for Industry Participants & Stakeholders
-
In-depth Analysis of the Global Leukocyte Reduction Filter Market
-
Historical, Current, and Projected Market Size in terms of Value
-
Potential & Niche Segments and Regions Exhibiting Promising Growth Covered
-
Industry Drivers, Restraints, and Opportunities Covered in the Study
-
Recent Industry Trends and Developments
-
Competitive Landscape & Strategies of Key Players
-
Neutral Perspective on Global Leukocyte Reduction Filter market performance
Segments
By Type
- Whole Blood Filtration
- Red Blood Cell Filtration
- Platelet Filtration
- Plasma Filtration
By Filter Type
- Membrane
- Antibacterial
- Antiviral
- Pocket
By Usage
By End-use Verticals
- Hospitals
- Blood Banks
- Laboratory
- Others
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Key Market Players Profiled in the Report
- Bıçakcılar
- Fresenius Kabi AG (Fresenius SE & Co. KGaA)
- Guangzhou Daji Medical Science and Technology Co., Ltd.
- Haemonetics Corporation
- Macopharma
- Mitra Industries (P) Ltd.
- Nanjing Shuangwei Biotechnology Co., Ltd.
- Nanjing Sunway Biomedical Technology Co., Ltd.
- PuriBlood Medical
- SB-KAWASUMI LABORATORIES, INC.
- Shandong Zhongbaokang Medical Implements Co., Ltd.
- TERUMO BCT, INC. (Terumo Corporation)
Competitive Landscape
-
Key players competing in the global leukocyte reduction filter market include Fresenius Kabi AG (Fresenius SE & Co. KGaA); Haemonetics Corporation; Macopharma; TERUMO BCT, INC. (Terumo Corporation); Nanjing Shuangwei Biotechnology Co., Ltd.; Bıçakcılar; SB-KAWASUMI LABORATORIES, INC.; PuriBlood Medical; Nanjing Sunway Biomedical Technology Co., Ltd.; Guangzhou Daji Medical Science and Technology Co., Ltd.; Shandong Zhongbaokang Medical Implements Co., Ltd.; Mitra Industries (P) Ltd.
-
These companies adopted development strategies including mergers, acquisitions, partnerships, collaboration, product launches, and production expansion to expand their consumer base worldwide.
Request For Customization
Enquiry Before Buying
Speak With Analyst
